News

The treatment for adults and adolescents with the type 2 inflammatory skin condition has been accepted for FDA review.

A prototype for a coral-reef-friendly sunscreen is more effective at preventing sunburn in mice than existing sunscreens.

Novan’s expected PDUFA date is January 5, 2024.

Researchers conducted a pooled data analysis using previous study data to determine the cream’s efficacy in patients ages 12 and up.

JNJ-2113 met primary endpoints in the FRONTIER 1 clinical trial.

Following a systematic review and observational study meta-analysis, researchers have uncovered an association between hidradenitis suppurativa and several atopic diseases.

The commander-in-chief’s cancerous tissue was successfully removed last month.

ICYMI, this week we had stories about accepted NDAs and sBLAs for VP-102 and nivolumab, overviews of rare dermatologic diseases for National Rare Disease Day, antioxidants for vitiligo and mental health, and more.

Transplant patients are at a higher risk of nonmelanoma carcinomas due to immunosuppressive therapies.

Following 2 phase 3 trials, the European Medicines Agency Committee for Medicinal Products for Human Use gives positive opinion on the use of ruxolitinib cream as a treatment for facial-involved non-segmental vitiligo.

Convatec’s InnovaBurn device manages surgical wounds and burns, including second-degree burns.

Innovative devices are always coming to the forefront of dermatology and contribute to patient satisfaction.

Research has begun to explore natural compounds that address the oxidative stress, autoimmunity, and altered melanogenesis that drive vitiligo pathogenesis.

Following a 72-week safety and efficacy trial, researchers have determined that 1% glycopyrronium bromide cream can reduce symptoms of hyperhidrosis.

Latin America presents a patchwork of challenges and opportunities in vitiligo management according to a review published in the Journal of Dermatological Treatment.

In this week’s Pointers with Dr Portela, the 208SkinDoc discusses basal cell carcinoma and Mohs surgery related to Jill Biden's most recent skin cancer diagnosis.

Each month, Dermatology Times® features a roundup of products trending in skin care. Find out what products are popular for the month of February.

Today is Rare Disease Day. The Food and Drug Administration (FDA) defined a rare disease as a condition affecting less than 200,000 people in the United States.

Learn more about what in-depth topics were covered in the February 2023 issue of Dermatology Times®.

The autoinflammatory condition is associated with mutations in the NOD2 gene and usually affects children younger than 4 years.

VP-102 could be the first FDA-approved treatment for molluscum contagiosum.

Nivolumab for completely resected stage IIB or IIC melanoma is also validated by the European Medicines Agency.

Researchers have linked the neurodegenerative disorder to several autoimmune diseases, including the rare skin condition bullous pemphigoid.

Researchers from Crown Laboratories say new treatment has shown improvements in skin concerns such as texture, wrinkles and sun damage.

Click here to answer this week's poll.

Researchers found that apremilast could reduce alcohol intake by more than half per day, on average.

ICYMI, this week we had stories about hidradenitis suppurativa coverage at Winter Clinical Miami, an NDA submission for roflumilast foam, an overview of the 2023 Biosimilars Report from Cardinal Health, and more.

In this week’s Pointers with Dr Portela, the 208SkinDoc shows how to find an ideal and affordable acne skin care routine.

Study participants saw a rapid decrease in inflammatory lesions with the once-daily antibiotic, antibacterial, and retinoid gel.

This week's edition of the Mainstream Patient features stories about treating dry eyelids, face masks for acne-prone skin, acne scar treatments, and more.